Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
January 16, 2024 07:00 ET
|
Eyenovia, Inc.
MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007 Part of corporate...
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 16:05 ET
|
Eyenovia, Inc.
Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline...
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
November 06, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for...
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
November 02, 2023 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for...
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
October 30, 2023 07:00 ET
|
Eyenovia, Inc.
Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) --...
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
October 09, 2023 07:00 ET
|
Eyenovia, Inc.
In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions Presentation to be made at the American Academy of...
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
September 21, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for...
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...
Eyenovia Announces $12 Million Registered Direct Offering
August 24, 2023 18:47 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
August 16, 2023 06:00 ET
|
Eyenovia, Inc.
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery Further leverages Eyenovia’s...